Loading data for ACET — first visit, this takes a few seconds.

Preisalarm

Adicet Bio Inc. (ACET)

NasdaqCM: ACET · Echtzeitkurs · USD

9.27

+0.16 (1.76%)

Zum Schluss: Aug 19, 2026, 3:29 PM

1.76% (1D)

Keine Daten verfügbar

Geld	6.35
Marktkapitalisierung	86.78 Mio
Umsatz (TTM)	n/a
Nettogewinn (TTM)	-98.97 Mio
Beta	1.59
EPS (ttm)	-10.42
KGV (TTM)	n/a
Forward-KGV	-2.35
KBV (TTM)	0.83
KUV (TTM)	n/a
Earnings Date	Nov 11, 2026

Brief	10.88
Volumen	16,321
Ø Vol. (20D)	92,351
Eröffnung	8.99
Vortagesschluss	9.11
Tagesspanne	8.99 - 9.48
52-Wk Range	6.01 - 17.44
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über ACET

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candida...

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum Jan 26, 2018

Mitarbeiter 102

Börse NasdaqCM

Tickersymbol ACET

Website https://www.adicetbio.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Adicet Bio 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -116.8 Mio, ein Rückgang von -0.27 %.

Finanzberichte

Gewinnüberraschung

Adicet Bio hat die Quartalszahlen am Aug 5, 2026 veröffentlicht:

Umsatz von $0 verfehlt die Erwartungen um $0, mit NaN% Wachstum im Jahresvergleich.

EPS von -1.99 verfehlt die Erwartungen um -0.35, mit 63.42% Wachstum im Jahresvergleich.

Nächste Ergebnisveröffentlichung

Adicet Bio Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am Nov 11, 2026, während der Handelszeiten.
Analysten erwarten einen Umsatz von ... Upgrade

Nachrichten

vor 1 Woche · MarketBeat

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy

Adicet Bio (NASDAQ:ACET) expects to report clinical data this quarter for its lead autoimmune program, ADI-001, also known as prula-cel, including results in lupus nephritis (LN) and systemic lupus er...

vor 1 Woche · Zacks

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

vor 1 Monat · Zacks

Is Adicet Bio (ACET) Stock Outpacing Its Medical Peers This Year?

Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.

vor 2 Monaten · MarketBeat

Adicet Bio Teases Autoimmune Data Catalysts, PSMA Plans at Jefferies Conference

Adicet Bio (NASDAQ:ACET) outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen S...

vor 2 Monaten · Zacks

Are Medical Stocks Lagging Adicet Bio (ACET) This Year?

Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.

Seite 1 von 2

Adicet Bio Inc. (ACET)